News | March 29, 2007

ACC3: Physicians Seeing Recovery of Dead Heart Tissue with Stem Cell Procedure

Dr. Nabil Dib, M.D., M.Sc., director of Cardiovascular Cell Therapy at University of California San Diego, reported how 23 patients in an FDA trial were safely transformed from advanced heart failure to recovery, during ACC 2007.

Author and researcher Christian Wilde has spent seven years studying preventive cardiovascular detection and treatment and has worked with Dr. Nabil Dib extensively in preparing his second breakthrough book, “Miracle Stem Cell Heart Repair, www.abigon.com.” This procedure proves for the first time in medical history that dead heart tissue can now be safely clinically repaired. It signifies hope for 22 million patients worldwide currently dying of congestive heart failure.

The book documents case histories and personal journeys of many of Dr. Dib's patients, as well as patients from other ongoing FDA trial successes who have undergone the one time minimally invasive procedure.

Many of Dr. Dib's patients in the trial have had four and even five previous heart attacks, which led them into heart failure. Many also presented with recorded ejection fractions (a measurement of the left ventricle's ability to pump blood) in the very low teens, 20s and 30s. Normal ejection fraction is between 50-70.

Until now, cardiologists have only been able to offer drugs, pacemakers and defibrillators as "band-aids" in treating advancing congestive heart failure. CHF patients may very soon have another promising long-term viable alternative in adult stem cell therapy — cells that the body will not reject and that do not cause tumor development.

Related Content

Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies | June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies | May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies | April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies | February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
News | Stem Cell Therapies | January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
Overlay Init